First-in-human, Randomized, Placebo-controlled, Double-blind, Dose-escalation Study of the Safety and Immunogenicity of NasoShield

Trial Profile

First-in-human, Randomized, Placebo-controlled, Double-blind, Dose-escalation Study of the Safety and Immunogenicity of NasoShield

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Mar 2018

At a glance

  • Drugs AdVAV (Primary)
  • Indications Anthrax
  • Focus Adverse reactions; First in man
  • Sponsors Altimmune
  • Most Recent Events

    • 28 Mar 2018 According to an Altimmune media release, first two cohorts have been enrolled in this trial.
    • 22 Jan 2018 Status changed from not yet recruiting to recruiting.
    • 11 Dec 2017 According to aN Altimmune media release, Company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for NasoShield
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top